A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Type 2 Diabetic Patients With Nonalcoholic Steatohepatitis (NASH).
Phase of Trial: Phase III
Latest Information Update: 30 May 2016
At a glance
- Drugs Rimonabant (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Acronyms STRONG2
- Sponsors Sanofi
- 28 Jul 2011 New source identified and integrated (European ClinicalTrials Database).
- 17 Jun 2009 Actual patient number (89) added as reported by ClinicalTrials.gov.
- 17 Jun 2009 Actual initiation date changed from 1 Dec 2007 to 1 Feb 2008 as reported by ClinicalTrials.gov.